Based on results from the phase 2 GEOMETRY mono-1 trial, the European Commission has approved capmatinib for patients with non–small cell lung cancer who have MET exon 14 skipping mutations, and a need for systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Patients with relapsed/refractory multiple myeloma experienced promising responses with REGN5458.
Treatment with 177Lu-PSMA-617 resulted in poor outcomes for patients with metastatic castration-resistant prostate cancer whose tumors had little to no prostate-specific membrane antigen expression.
Results from the phase 3 AENA trial led to the United Kingdom’s Medicine and Healthcare products Regulatory Agency accepting a marketing authorization application for aumolertinib for review in patients with locally advanced or metastatic non–small cell lung cancer with activating EGFR mutations, and those with locally advanced or metastatic EGFR T790M mutation–positive non–small cell lung cancer.
Results from the WSG-ADAPT-HER2+/HR- study showed promising survival rates with pathological complete response when patients with HER2-positive, hormone receptor-negative early breast cancer were treated with a de-escalated dose of trastuzumab plus pertuzumab without or without paclitaxel over a 12-week period.
Xiuning Le, MD, PhD, spoke about the use of ctDNA biomarkers and why research should continue for those with advanced non–small cell lung cancer with high MET-amplification being treated with tepotinib.
Nora Janjan, MD, MPSA, MBA, spoke with CancerNetwork® about the latest perspective from the journal ONCOLOGY® on how roles and responsibilities of academic clinicians in reporting of conflicts of interest influence oncology research.
Xiuning Le, MD, PhD, spoke about unmet needs in patients with advanced non–small cell lung cancer with high MET-amplifications and why tepotinib may be a good treatment option.
Older patients with acute myeloid leukemia who were treated with decitabine experienced comparable outcomes vs daunorubicin and cytarabine.
Nutritional markers such as body mass index, weight loss, and albumin should be assessed to identify pre-operative malnutrition in patients with gynecologic cancers.
The highly selective JAK inhibitor momelotinib is being considered for the treatment of patients with myelofibrosis by the FDA following submission of a new drug application for this indication.
A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
A panel of experts review two patient cases to elucidate data in the adjuvant setting of non–small cell lung cancer.
Karen L. Reckamp, MD, spoke about safety signals that emerged in the Lung-MAP nonmatched phase 2 substudy S1800A and what the next steps are for the combination of ramucirumab/pembrolizumab in patients with non–small cell lung cancer pretreated with chemotherapy and immunotherapy
Patients with gastrointestinal stromal tumors may benefit from 68GA-RM26 PET/CT vs 18F-FDG, according to findings presented at the 2022 Society of Nuclear Medicine & Molecular Imaging Annual Meeting.
Shubham Pant, MD, highlights the importance of tailoring treatment in patients with pancreatic cancer by exploring biomarkers.
The 3-year follow-up update from the phase 2 ZUMA-2 trial showed continued responses for patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.
Rahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.
Independent factors such as the integrated clinical radiomics model and 18F-FDG PET/CT radiomics signature may be predictive of progression-free survival in breast cancer.
Patients with heavily pretreated multiple myeloma appeared to benefit from treatment with talquetamab and daratumumab plus hyaluronidase-fihj.
Biagio Ricciuti, MD, spoke about the 3-year follow-up and prolonged survival benefit in patients with non–small cell lung cancer who had very high PD-L1 expression of 90% or more.
This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.
Data from the SPOTLIGHT trial indicate agreement among trained PET readers was highly concordant with use of 18F-rhPSMA-7.3 imaging for recurrent prostate cancer.
Patients with treatment-naïve chronic lymphocytic leukemia who were treated with venetoclax and obinutuzumab with or without ibrutinib experienced a progression-free survival benefit compared with standard chemoimmunotherapy.
Richard Kim, MD, highlights future research efforts examining immunotherapy/chemotherapy combinations for patients with metastatic colorectal cancer.
Karen L. Reckamp, MD, spoke about the rationale behind the Lung-MAP S1800A substudy of pembrolizumab plus ramucirumab for patients with non–small cell lung cancer and the topline results from 2022 ASCO.
In this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.
Despite women with multiple myeloma being more likely to have certain cytogenetic risk factors vs men, sex did not appear to impact efficacy.
Patients with uterine carcinosarcoma who underwent sentinel lymph node biopsy or systemic lymph node dissection did not experience a difference in progression-free survival or overall survival.
Tony S. Mok, MD, spoke about the use of capmatinib plus pembrolizumab in patients with previously untreated non–small cell lung cancer who were MET unselected and had PD-L1 expression of 50% or more.
